HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin D Benefits Don’t Extend To Preventing Depression In Older Adults – Study

Executive Summary

Vitamin D3 intake didn’t prevent depression among consumers 50 and up, according to results of a five-year study published in the Journal of the American Medical Association. The research was among first studies “statistically powered” to answer long-standing question on vitamin’s benefit on mood.

You may also be interested in...



VITAL Ancillary Study Results Cast More Doubt On Cardio Benefit From Omega-3, Vitamin D

AF events occurred in 469 (3.7%) of subjects receiving EPA and DHA supplements compared to 431 (3.4%) of participants receiving placebos. In vitamin D3 and placebo comparison, AF events occurred in 469 (3.7%) versus 431 (3.4%).

Poor Results For Supplementation To Curb Depression In First-Of-Kind Study

Supplementation with omega-3s, folic acid, vitamin D3, calcium and selenium did not reduce MDD onset in overweight subjects with history of depression, according to first RCT on effectiveness of two nutritional strategies and their combination in preventing depression among high-risk subjects.

Kyowa Hakko Expands Probiotic Supplies With ‘Dead’ Ingredient To Battle Eye Fatigue

Kyowa Hakko unveils supplement ingredient Eyemuse, a heat-treated “parabiotic” found to reduce eye fatigue, filter blue light and support a balanced immune response. CRN campaign educates retailers, consumers about probiotics and helps retailers improve handling of the products.

Topics

UsernamePublicRestriction

Register

RS150422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel